News

Viridian's VRDN-003, a subcutaneous therapy for thyroid eye disease, has demonstrated positive data in a Phase 1 clinical study, with an extended half-life of 40-50 days. The company plans to initiate global pivotal trials in mid-2024, aiming to transform TED treatment with less frequent dosing intervals.

Marc Gleeson, CEO of Azura, sat down with David Hutton, Managing Editor at Ophthalmology Times to discuss the recent positive results from the Phase 2 clinical trial of AZR-MD-001 in patients with contact lens discomfort.

NCX 470, a novel nitric oxide-donating bimatoprost eye drop, is the company’s lead product candidate in Phase 3 clinical development for IOP lowering in patients with open-angle glaucoma or ocular hypertension.

According to the company, the study met its primary endpoint and showed significant and clinically meaningful improvements in multiple symptoms of contact lens discomfort and signs of concomitant meibomian gland dysfunction.

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.

A team of researchers from Tokyo Medical and Dental University have developed models based on machine learning that predict long-term visual acuity in patients with high myopia, one of the top three causes of irreversible blindness in many regions of the world.

Eric Jennings, MD, from Woolfson Eye Institute, discusses the SMARTCataract cloud-based app from Alcon and its implementation where he practices with David Hutton, Managing Editor, Ophthalmology Times.

According to the company, the acquisition will extend its leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment.

The research marks the first attempt at integrating a photoactivatable anti-angiogenic agent with a photosensitizer into a single nanoformulation for AMD treatment.

Randomization has been completed and, according to the company, topline data is expected during the third quarter of 2024.

The kidney and eye are structurally and functionally similar, and the diseases of the organs may present similarly and via common pathways.

In this episode, Neda Shamie, MD, and Peter J. McDonnell, MD, discuss the benefits and challenges of implementing the many options from the premium lens pipeline into practice, emphasizing the importance of customization based on patients' lifestyles and expectations, while also addressing concerns and sharing their positive experiences with the evolving technology in the field.

According to the company, OCU410 is a modifier gene therapy product candidate being developed for dry AMD

Additional testing is needed to ensure accuracy across different groups.

LambdaVision seeks to cure genetic blindness with a protein-based artificial retina. Harnessing microgravity in low-Earth orbit, the company collaborates with NASA and the ISS to perfect its manufacturing process.

A Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser, the Eagle is intended for use in performing selective laser trabeculoplasty.

Ophthalmology witnessed a transformative year with 12 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.

The system hopes to use optical coherence tomography (OCT), while at the same time, leverage air and ultrasonic pulses to excite the mechanical waves in the cornea, enabling the detection of normotensive glaucoma.

TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and s being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.

ROP can be a disease that affects both the retinal and choroidal vasculatures.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD.

The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.

Japanese investigators may have found a way of predicting which patients will develop intraocular inflammation in retrospective study.

According to the company, the device is designed to offer a non-surgical solution for patients suffering from keratoconus, corneal irregularities, photophobia, and presbyopia.

David A. Eichenbaum, MD, highlighted new therapies such as faricimab and high-dose aflibercept to reduce the burden of diseases like macular degeneration and diabetic eye conditions while improving patient outcomes during his presentation at EyeCon 2023.

MACs categorize goniotomy, canaloplasty, cyclophotocoagulation as experimental; glaucoma specialists speak out.

Patients considered vitamin D deficient had a risk of noninfectious uveitis more than twice that of their counterparts without vitamin D deficiency.